Predicting resistance to piperacillin-tazobactam, cefepime and meropenem in septic patients with bloodstream infection due to gram-negative bacteria
Clinical Infectious Diseases Nov 08, 2017
Vazquez-Guillamet MC, et al. - Researchers here aimed at developing clinical decision trees able to identify patients with gram-negative bacteria (GNB) infection at low risk for resistance to piperacillin-tazobactam (PT), cefepime (CE), and meropenem (ME). With simple variables, clinical decision trees seemed to have the potential for distinguishing patients at low, intermediate, or high risk of resistance to PT, CE, and ME.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries